Steven Libutti, MD, FACS, is a distinguished surgical-oncologist, physician-scientist, and leader who serves as William N. Hait Director, Rutgers Cancer Institute—NJ’s only National Cancer Institute-designated Comprehensive Cancer Center; Vice Chancellor for Cancer Programs, Rutgers Biomedical and Health Sciences; Distinguished Professor of Surgery, Rutgers Robert Wood Johnson Medical School; and Senior Vice President of Oncology Services, RWJBarnabas Health—NJ’s largest health system.

Libutti graduated Harvard College-magna cum laude and received his medical degree from College of Physicians and Surgeons, Columbia University. He completed residency in surgery at New York-Presbyterian Hospital, followed by a fellowship in surgical oncology at National Cancer Institute (NCI), where Libutti became a tenured Senior Investigator and Chief of the Tumor Angiogenesis Section, Surgery Branch. Following, he served as Director, Montefiore Einstein Center for Cancer Care and Associate Director, Albert Einstein Cancer Center for eight years prior to joining Rutgers and RWJBarnabas Health.

Libutti is an internationally known expert in management of neuroendocrine tumors and Past President of American Association of Endocrine Surgeons. His clinical practice focuses on gastrointestinal malignancies including cancers of the liver and pancreas. The recipient of funding from NCI for over 25 years, Libutti’s research focuses on developing novel cancer therapies through an understanding of the tumor microenvironment and a better understanding of the tumor suppressor genes MEN1 and FILIP1L. He has published over 325 peer-reviewed journal articles, holds eleven U.S. patents, is Editor-in-Chief Emeritus of Springer-Nature Journal Cancer Gene Therapy and member of AAP (Association of American Physicians). Libutti has navigated Rutgers Cancer Institute’s P30-CCSG Comprehensive Cancer Center Award through two competitive renewals, most recent of which in 2023 achieved the Center’s highest score placing it among the top centers in the US. Under his leadership, the Jack and Sheryl Morris Cancer Center-New Jersey’s first free standing cancer hospital opened in 2025.